Trials / Completed
CompletedNCT00038662
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Abbott · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atrasentan |
Timeline
- Start date
- 2002-05-01
- First posted
- 2002-06-04
- Last updated
- 2006-08-15
Locations
40 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00038662. Inclusion in this directory is not an endorsement.